These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 12091636)
1. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.5.8. Cardiovascular risks. Immunosuppressive therapy. EBPG Expert Group on Renal Transplantation Nephrol Dial Transplant; 2002; 17 Suppl 4():30-1. PubMed ID: 12091636 [TBL] [Abstract][Full Text] [Related]
2. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.3.1 Long-term immunosuppression. Late steroid or cyclosporine withdrawal. EBPG Expert Group on Renal Transplantation Nephrol Dial Transplant; 2002; 17 Suppl 4():19-20. PubMed ID: 12091624 [TBL] [Abstract][Full Text] [Related]
3. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.5.1. Cardiovascular risks. Cardiovascular disease after renal transplantation. EBPG Expert Group on Renal Transplantation Nephrol Dial Transplant; 2002; 17 Suppl 4():24-5. PubMed ID: 12091628 [TBL] [Abstract][Full Text] [Related]
4. Influence of the new immunosuppressive combinations on arterial hypertension after renal transplantation. Morales JM Kidney Int Suppl; 2002 Dec; (82):S81-7. PubMed ID: 12410861 [TBL] [Abstract][Full Text] [Related]
5. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.3.3. Long-term immunosuppression. Toxicity of immunosuppression. EBPG Expert Group on Renal Transplantation Nephrol Dial Transplant; 2002; 17 Suppl 4():21-3. PubMed ID: 12091626 [TBL] [Abstract][Full Text] [Related]
6. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.5.3. Cardiovascular risks. Hyperlipidaemia. EBPG Expert Group on Renal Transplantation Nephrol Dial Transplant; 2002; 17 Suppl 4():26-8. PubMed ID: 12091631 [TBL] [Abstract][Full Text] [Related]
7. Cardiovascular risk profile with the new immunosuppressive combinations after renal transplantation. Morales JM; Dominguez-Gil B J Hypertens; 2005 Sep; 23(9):1609-16. PubMed ID: 16093902 [TBL] [Abstract][Full Text] [Related]
8. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.5.2. Cardiovascular risks. Arterial hypertension. EBPG Expert Group on Renal Transplantation Nephrol Dial Transplant; 2002; 17 Suppl 4():25-6. PubMed ID: 12091630 [TBL] [Abstract][Full Text] [Related]
9. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.3.2. Long-term immunosuppression. Therapy conversion. EBPG Expert Group on Renal Transplantation Nephrol Dial Transplant; 2002; 17 Suppl 4():20-1. PubMed ID: 12091625 [TBL] [Abstract][Full Text] [Related]
10. A long-term study on hyperlipidemia in stable renal transplant recipients. Tse KC; Lam MF; Yip PS; Li FK; Lai KN; Chan TM Clin Transplant; 2004 Jun; 18(3):274-80. PubMed ID: 15142048 [TBL] [Abstract][Full Text] [Related]
11. Effect of immunosuppressive agents on long-term survival of renal transplant recipients: focus on the cardiovascular risk. Boots JM; Christiaans MH; van Hooff JP Drugs; 2004; 64(18):2047-73. PubMed ID: 15341497 [TBL] [Abstract][Full Text] [Related]
12. Risk factors for and management of post-transplantation cardiovascular disease. Fellström B BioDrugs; 2001; 15(4):261-78. PubMed ID: 11437691 [TBL] [Abstract][Full Text] [Related]
13. Assessing the relative risk of cardiovascular disease among renal transplant patients receiving tacrolimus or cyclosporine. Jardine AG Transpl Int; 2005 Apr; 18(4):379-84. PubMed ID: 15773954 [TBL] [Abstract][Full Text] [Related]
14. [Hypertension after kidney transplantation]. Racki S Lijec Vjesn; 2006; 128(11-12):373-8. PubMed ID: 17212200 [TBL] [Abstract][Full Text] [Related]
15. Obesity, metabolic syndrome and diabetes mellitus after renal transplantation: prevention and treatment. Wissing KM; Pipeleers L Transplant Rev (Orlando); 2014 Apr; 28(2):37-46. PubMed ID: 24507957 [TBL] [Abstract][Full Text] [Related]
16. [Cardiovascular risks of corticosteroids]. Szwebel TA; Le Jeunne C Presse Med; 2012 Apr; 41(4):384-92. PubMed ID: 22361027 [TBL] [Abstract][Full Text] [Related]
17. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.5.4. Cardiovascular risks. Post-transplant diabetes mellitus. EBPG Expert Group on Renal Transplantation Nephrol Dial Transplant; 2002; 17 Suppl 4():28. PubMed ID: 12091632 [TBL] [Abstract][Full Text] [Related]
18. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.10. Pregnancy in renal transplant recipients. EBPG Expert Group on Renal Transplantation Nephrol Dial Transplant; 2002; 17 Suppl 4():50-5. PubMed ID: 12091650 [TBL] [Abstract][Full Text] [Related]
19. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.5.7. Cardiovascular risks. Obesity and weight gain. EBPG Expert Group on Renal Transplantation Nephrol Dial Transplant; 2002; 17 Suppl 4():29-30. PubMed ID: 12091635 [TBL] [Abstract][Full Text] [Related]
20. [Metabolic disorders in renal transplant recipients]. Mikolasević I; Jelić I; Sladoje-Martinović B; Orlić L; Zivcić-Cosić S; Vuksanović-Mikulicić S; Mijić M; Racki S Acta Med Croatica; 2012 Jul; 66(3):235-41. PubMed ID: 23441539 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]